Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2025

An Zhao, Ning Ye, Mei Jie, Yang Chenlu, Yang Xiaodong

Abstract excerpt

OBJECTIVES: Adjuvant chemotherapy (ACT) for patients with stage IB lung adenocarcinoma (LUAD) is controversial, particularly in those with epidermal growth factor receptor (EGFR) mutations. This study aims to evaluate the efficacy of ACT in stage IB LUAD with Grade 3 and explore the prognostic impact of EGFR mutations status on chemotherapy effectiveness. METHODS: We identified 707 high-risk (Grade 3) stage IB...

Read the complete abstract on PubMed

Topics

Humans
ErbB Receptors
Male
Female
Adenocarcinoma of Lung
Lung Neoplasms
Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Prognosis

Mutation

Middle Aged

Neoplasm Staging

Aged

Neoplasm Grading

Retrospective Studies

Adult

Treatment Outcome

Source

Identifiers

PMID: 40132294
DOI: 10.1016/j.lungcan.2025.108507

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.PMID 40132294Read ↗

Prognostic impact of epidermal growth factor receptor mutation in grade 3 stage IA lung adenocarcinomas.Semantic proximity Read ↗

The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.Semantic proximity Read ↗

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.Semantic proximity Read ↗

Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.Semantic proximity Read ↗

Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

EGFR Mutation Impacts Recurrence in High-Risk Early-Stage Lung Adenocarcinoma in the IASLC Grading SystemSemantic proximity Read ↗

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.Semantic proximity Read ↗

EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.Semantic proximity Read ↗

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma.Semantic proximity Read ↗

Risk Stratification and Adjuvant Chemotherapy Based on Clinical Risk Scores of Patients with Stage IB-IIA Non-Small Cell Lung CancerSemantic proximity Read ↗

Effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with sensitive EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.